Carl D Regillo MD

Retinal Disease

Director, Wills Eye Retina Service

4060 Butler PikeSte 200Plymouth Meeting, PA 19462
Phone+1 800-331-6634
Fax+1 267-420-1360

Dr. Regillo is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Regillo's full profile Already have an account?

Summary

Carl Regillo, MD, is a retina specialist located in Philadelphia, PA. He obtained his MD from Harvard Medical School and completed his internship in internal medicine at Mass General Brigham. His residency and fellowship in surgical retina and vitreous were completed at Wills Eye Hospital. Dr. Regillo holds positions at multiple institutions, including Director of the Retina Service at Wills Eye Hospital, Professor at Thomas Jefferson University Hospital. He is also a partner at Mid Atlantic Retina. His clinical expertise includes diabetic retinopathy, macular degeneration, and retina surgery. He has over 300 peer-reviewed publications in the field of ophthalmology, is invited to speak worldwide, and is involved in numerous clinical trials focused on treatments for retinal conditions. He was listed among the 50 most influential ophthalmologist worldwide.

Education & Training

Sidney Kimmel Medical College at Thomas Jefferson University/Wills Eye HospitalFellowship, Surgical Retina and Vitreous, 1992 - 1994
Sidney Kimmel Medical College at Thomas Jefferson University/Wills Eye HospitalResidency, Ophthalmology, 1989 - 1992
Mass General Brigham/Brigham and Women's HospitalInternship, Internal Medicine, 1988 - 1989
Harvard Medical SchoolMD, 1984 - 1988
Harvard Medical SchoolClass of 1988

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

NJ State Medical License 1998 - 2027
PA State Medical License 1990 - 2026
CA State Medical License 1994 - 1998
MA State Medical License 1984 - 1988
American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

Philadelphia Magazine Castle Connolly
The Ophthalmologist Power List (Top 50 most influential people in the world of ophthalmology) The Ophthalmologist, 2018, 2020, 2022, 2024-2026
Top 150 Ophthalmologists in the US Newsweek, 2022

Clinical Trials

Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration Start of enrollment: 2011 Jun 09
COMPLETED
PHASE1, PHASE2
Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy Start of enrollment: 2011 Jun 16
COMPLETED
PHASE1, PHASE2
Ozurdex With Rescue Lucentis for Treating Macular Edema Secondary to Retinal Vein Occlusion
UNKNOWN
NA

Publications & Presentations

PubMed

Photic retinal injury: Time to move beyond case reports-A PRISM Study Group perspective.
Ashish Sharma, Carl D Regillo, Baruch D Kuppermann,
Eye. 2026-08-07
Expert Opinion: Management of Intraocular Inflammation and Vasculitis After Intravitreal Pegcetacoplan for Geographic Atrophy.
Thomas A Albini, Steven Yeh, Carl D Regillo, Roy Schwartz, Philip J Ferrone
Ophthalmic Surgery, Lasers & Imaging Retina. 2026-08-01
Real-World Safety of Intravitreal Complement Inhibitor Avacincaptad Pegol for Geographic Atrophy.
Alexander Shaer, Tadashi Yokoi, Eshani Ragam, Joseph Weintraub, Benjamin Lipchin
Journal of Vitreoretinal Diseases. 2026-07-19

Journal Articles

Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.
Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM, Ophthalmology
Pegaptanib for neovascular age-related macular degeneration.
Gragoudas ES, Adamis AP, Cunningham ET, Jr, N Engl J Med
Safety results of two phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage.
Kupperman BD, Thomas EL, de Smet MD, Am J Ophthalmol

Books/Book Chapters

Duane’s Clinical Ophthalmology.
Chapter: Indocyanine green angiography
Weichel ED, Regillo CD, Maguire JIEditors: Tasman W, Jaeger EA.Lippincott-Williams & Wilkins, Philadelphia
Duane’s Clinical Ophthalmology.
Chapter: Vitrectomy
McCabe FJ, Regillo CD, Benson WEEditors: Tasman W, Jaeger EA.Lippincott-Williams & Wilkins, Philadelphia
Retinal and Vitreoretinal Diseases and Surgery.
Chapter: Surgical management of proliferative vitreoretinopathy
Sprin MJ, Regillo C, Lewis HEditors: Boyd S, Cortez R, Sabates N.Jaypee-Highlights, New Dehli

Abstracts/Posters

Anecortave acetate administered sub-tenon’s retrobulbar with and without Visudyne PDT in patients with subfoveal age-related macular degeneration (AMD)-Clinical safety...
D’Amico DJ, Duker J, Regillo C, Schneebaum C, Beasley C, Invest Ophthalmol Vis Sci
Scleral buckling procedures decrease central retinal artery mean blood flow velocity.
Regillo C, Sergott R, Brown G, Invest Ophthalmol Vis Sci
Repair of AIDS retinitis-related retinal detachments with vitrectomy and silicone oil.
Regillo C, Vander J, Fischer D, Belmont J, Kleiner R, Invest Ophthalmol Vis Sci

Lectures

Anti-VEGF therapy for CRVO and BRVO.
Newport Beach, CA
Neovascular AMD treatment update 2012.
Multiple locations
Phamacologic vitreolysis and future management of symptomatic vitreomacular adhesion.
A CME program by Retina Today and NRI. Aspen, CO

Press Mentions

EyePoint Announces Positive 6-Month Results for the Phase 2 VERONA Clinical Trial of Duravyu for DMEJanuary 16th, 2025
AMD, DME Therapies Aimed at Reducing Treatment Burden Shine at AAO 2024November 1st, 2024
EyePoint Pharmaceuticals Doses First Patient in Phase 3 LUGANO Trial for Wet AMD Therapy DuravyuOctober 24th, 2024